• Adjuvant Datopotamab Deruxtecan with Drug Combination in Patients with High‑Risk Muscle‑Invasive Urothelial Carcinoma

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France Italy Poland Spain

  • Study of the Safety, Tolerability and Efficacy of Oral Vafidemstat in Adults with Phelan‑McDermid Syndrome (HOPE‑2)

    Not yet recruiting

    2 1 1
    Investigated Drugs:
    Spain

  • Study of Dostarlimab in Young Women with Newly Diagnosed MMR‑deficient Endometrial Cancer Who Want to Preserve Fertility

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium

  • Randomized Placebo‑Controlled Trial of Cenerimod for Efficacy and Safety in Adults with Systemic Lupus Erythematosus and Active Lupus Nephritis

    Not yet recruiting

    3 1
    Investigated Diseases:
    Investigated Drugs:
    Germany Poland Spain

  • ImmunoPET with 89Zr‑trastuzumab to predict response to trastuzumab deruxtecan in patients with locally advanced or metastatic breast cancer

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    Belgium

  • Phase 3 Study of Oral Orforglipron vs Weekly Dulaglutide in Children and Adolescents (10‑<18 years) with Type 2 Diabetes

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium Italy Spain

  • Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Face and Neck Atopic Dermatitis

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    Investigated Drugs:
    Denmark Germany Poland Portugal

  • Effectiveness of a second dose of RSV subgroup A 847A and subgroup B 847B versus primary dose to prevent respiratory syncytial virus infection in immunocompromised adults

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    Denmark

  • Study of ivonescimab plus enfortumab vedotin versus pembrolizumab plus enfortumab vedotin in previously untreated locally advanced or metastatic urothelial carcinoma

    Not yet recruiting

    4 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Spain

  • Phase 2b Study of VXB-221 and VXB-213 Protein Vaccine for Prevention of Respiratory Syncytial Virus and Human Metapneumovirus Infections in Adults ≥60 Years

    Not yet recruiting

    2 1
    Czechia Estonia Finland The Netherlands Poland Spain

powered by